NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary Chapter: 10 - Musculoskeletal and joint diseases 
Notes:

Any drug not listed on the Formulary should be considered Non-Formulary - Not recommended for prescribing
10.01.03 Drugs which suppress the rheumatic disease process
BLMK APC Biologics Treatment pathway for Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis (nrAxial SpA) BLMK APC Treatment Pathway for Active Psoriatic Arthritis (non-Axial PsA) after inadequate response to DMARDs BLMK APC Treatment pathway for Moderate Rheumatoid Arthritis BLMK APC Treatment Pathway for Severe Rheumatoid Arthritis JPC Biologics Treatment Pathway for ankylosing spondylitis and Non-radiographic Axial Spondyloarthritis (March 2018) NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199) NICE TA375:Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis Rheumatology Overarching shared care guideline
10.01.03 Gold
10.01.03 Penicillamine
10.01.03 Antimalarials
10.01.03 Drugs affecting the immune response
10.01.03 Cytokine modulators
10.01.03 Sulfasalazine
BLMK APC Biologics Treatment pathway for Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis (nrAxial SpA) BLMK APC Treatment Pathway for Active Psoriatic Arthritis (non-Axial PsA) after inadequate response to DMARDs BLMK APC Treatment pathway for Moderate Rheumatoid Arthritis BLMK APC Treatment Pathway for Severe Rheumatoid Arthritis JPC Biologics Treatment Pathway for ankylosing spondylitis and Non-radiographic Axial Spondyloarthritis (March 2018) NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199) NICE TA375:Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis Rheumatology Overarching shared care guideline

Sulfasalazine

SCG
Restricted Drug Restricted

500mg Enteric Coated Tablets
250mg/5mL Suspension

To be prescribed by Consultant Rheumatologist for the treatment of active inflammatory arthritis in adult patients in accordance with JPC Shared Care Guidelines.

September 2024 – Pfizer have discontinued the Salazopyrin brand, must be prescribed as generic.

Entry reviewed : September 2024

 

BNF BNFc SPC
Rheumatology Overarching shared care guideline Sulfasalazine - Information for GPs (appendix to the overarching Rheumatology shared care guideline)
Classifications
GREEN
May be initiated in any care setting
Amber SPA
Specialist to advise therapy and provide first 28 days supply, continuation in Primary Care
Amber SPIS
Specialist to initiate and stabilise medicine prior to continuation in Primary Care
SCG
To be prescribed as per Shared Care Guidance. If no SCG in place status reverts to red.
RED
Red medicines are designated as specialist only medicines which should only be prescribed by a specialist, usually within secondary care (either due to the requirement for specialist knowledge, long-term monitoring requirements, or restrictions that mean medicine supplies are only available to hospitals).
DNP
A decision has been made either locally and/or nationally not to routinely commission this preparation. Do not prescribe.
SELF
To be purchased over the counter. May be prescribed for chronic, long term conditions or on admission to hospital if essential.